ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2022 and some content may be unavailable. To unlock all content for 2022, please visit the archives.

Abstract: SA-OR01

Long-Term Renal Outcomes of COVID-19-Associated Nephropathy (COVAN)

Session Information

Category: Coronavirus (COVID-19)

  • 000 Coronavirus (COVID-19)


  • Giannini, Gabriel A., Arkana Laboratories, Little Rock, Arkansas, United States
  • Caza, Tiffany, Arkana Laboratories, Little Rock, Arkansas, United States
  • May, Rebecca, Arkana Laboratories, Little Rock, Arkansas, United States
  • Mohamed, Muner, Stamford Hospital, Stamford, Connecticut, United States
  • Cassol, Clarissa Araujo, Arkana Laboratories, Little Rock, Arkansas, United States
  • Sharma, Shree G., Arkana Laboratories, Little Rock, Arkansas, United States
  • Larsen, Christopher Patrick, Arkana Laboratories, Little Rock, Arkansas, United States
  • Velez, Juan Carlos Q., Ochsner Health Network LLC, New Orleans, Louisiana, United States

COVID-19-associated nephropathy (COVAN) is a type of collapsing glomerulopathy that leads to acute kidney injury (AKI) and overt proteinuria in individuals with apolipoprotein L1 (APOL1) polymorphism infected with SARS-CoV-2. Although the severity of the acute presentation of COVAN is well described, the long-term renal prognosis has not been clearly established.


We retrospectively identified native kidney biopsies from patients with diagnosis of COVAN discharged alive between January 2020 and March 2021. Time of biopsy pathological and clinical data were collected. We performed APOL1 genotyping for G1/G2 risk alleles. We examined the rate of end-stage kidney disease (ESKD), de novo or progressive chronic kidney disease (CKD) and death. Factors associated with those outcomes were assessed by logistic regression.


A total of 43 patients with COVAN with median follow-up at 244 days were included. Mean age was 53 ± 12 years (range 30-78), 49% women, and 85% were of African descent. High-risk APOL1 genotypes were found in 86%. Most presented with AKI (91%) and nephrotic-range proteinuria (81%). Sixteen patients required dialysis at presentation (AKI-RRT), 8 of which reached ESKD and dialysis dependence at follow-up. Additionally, 6 patients without AKI-RRT developed ESKD and required dialysis at follow-up. Forty patients (93%) either developed de novo CKD or progressed to advanced stage of CKD [mean serum creatinine (sCr) 3.1 ± 1.9 mg/dL]. Overall, 35% reached the combined endpoint of ESKD, progressive CKD or death.

Predictive factors of ESKD included older age (59.1 ± 13.9 vs. 50.4 ± 10.7 years, p=0.03), increased sCr at time of biopsy (9.4 ± 3.2 vs. 6.0 ± 4.9, p=0.03), increased glomerular obsolescence (52.8 ± 21.3 vs. 25.0 ± 23.2%, p=0.0005), and IFTA [moderate-severe vs. mild, OR 9.8 (CI: 1.1-85.2), p=0.03]. AKI-RRT, sex, proteinuria at the time of biopsy, and absence vs. presence of an APOL1 high-risk genotype were not predictive of ESKD.


COVAN is associated with ominous long-term renal sequelae. Serum creatinine at time of biopsy, patient age, glomerular obsolescence, and IFTA are associated with greater risk of ESKD.